1-2 of 2
Stew Kroll
Close
Sort by
Journal Articles

Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Jacob P. Laubach, MD, Noopur Raje, MD, Andrew J. Yee, MD, Philippe Armand, MD PhD, Robert L. Schlossman, MD, Jacalyn Rosenblatt, MD, Michael G. Martin, MD, Craig Reynolds, MD, Kenneth H. Shain, MD PhD, Ira Zackon, MD, Laura V. Stampleman, MD, Emily Lai, BS, Aaron M. Caola, BS, Joseph M. Cappuccio, BS, Bradley Rivotto, BS, Kaitlen Reyes, DNP, Alexandra Savell, BS, Patrick Henrick, BS, Tillman Pearce, MD, Damian Handisides, Stew Kroll, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Irene M. Ghobrial, MD
Journal: Blood
Blood (2016) 128 (22): 2122.
https://doi.org/10.1182/blood.V128.22.2122.2122
Published: 2016
Journal Articles

A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

Jacob P. Laubach, MD, Noopur S. Raje, MD, Andrew J. Yee, MD, Philippe Armand, MD PhD, Robert L. Schlossman, MD, Jacalyn Rosenblatt, MD, Jeffrey Matous, MD, Jacquelyn Hedlund, MD, Michael G Martin, MD, Craig Reynolds, MD, Kenneth H. Shain, MD PhD, Ira Zackon, MD, Laura V. Stampleman, MD, Erica N Boswell, BS, Stacey Chuma, BSN, Rebecca Liguori, MS, Stephanie Mar, Damian Handisides, Stew Kroll, Kenneth C. Anderson, MD, Paul G. Richardson, Irene M. Ghobrial, MD
Journal: Blood
Blood (2014) 124 (21): 2142.
https://doi.org/10.1182/blood.V124.21.2142.2142
Published: 2014